Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penpulimab in Metastatic Pheochromocytoma/Paraganglioma
NCT05885399Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2023
- Primary completion
- Mar 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of penpulimab in pheochromocytoma and Paraganglioma (PGL), sponsored by Peking Union Medical College Hospital. Primary endpoints: Objective Response Rate at Cycle 3 and Disease Control Rate at Cycle 3. Status: unknown.
02
Drugs
penpulimab
03
Conditions
pheochromocytomaParaganglioma (PGL)
Beyond the preview
Go deeper on NCT05885399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05885399.